CHMP positive opinion for upadacitinib (Rinvoq) for the treatment of adults with giant cell arteritis – Abbvie
AbbVie announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq 15 mg, once daily) for… read more.
